Compare Amgen, Inc. (AMGN) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Sanofi SA — how do they compare? Amgen, Inc. trades at $385.65 (market cap $208.49B), while Sanofi SA trades at $42.48 (market cap $101.81B). The key difference: Amgen, Inc. is far larger — about 2× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (5.7%). Which is the better fit depends on your goals — on Pluang, investors hold Amgen, Inc. for 72 Days and Sanofi SA for 93 Days on average.
| AMGN | SNY | |
|---|---|---|
Market Cap | $208.49B | $101.81B |
Volume | 8,466,925 | 2,244,698 |
Sector | Health | Health |
52-Week High | $444.12 | $52.34 |
52-Week Low | $271.18 | $41.33 |
Typical Hold Time | 72 Days | 93 Days |
Enterprise Value | $251.81B | $121.57B |
Dividend Yield | 2.61% | 5.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $385.65, up 2.47% today, with a bullish technical signal and strong earnings beats in recent quarters. The company posted $36.75B in 2025 revenue, with a net income margin of 22.95%, and maintains a robust pipeline highlighted by IMDELLTRA progress. Analysts show a consensus buy rating with a $393.72 price target, reflecting confidence in growth drivers and financial discipline.
Outlook is positive due to consistent earnings outperformance and defensive stock attributes, but risks include high debt levels and competitive pressures. The stock offers a dividend yield and is positioned for steady growth, though investors should monitor execution of late-stage pipeline developments and macroeconomic factors affecting healthcare sectors.
SNY trades at $42.48, down 0.26% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue growth to $46.72B in 2025. Valuation ratios include a P/E of 23.15 and P/B of 1.29, while profitability metrics show a net income margin of 8.09%. Recent news highlights strategic partnerships and FDA approvals, supporting growth initiatives.
The outlook for SNY is mixed, with positive earnings momentum and analyst buy ratings offset by bearish technical trends and projected net cash flow declines in 2026. Investment opportunities lie in its diversified revenue base and new product launches, but risks include competitive pressures and potential pipeline setbacks. Investors should weigh strong fundamentals against near-term cash flow challenges and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
